Leerink Partners Reiterates Outperform Rating on Aurinia Pharmaceuticals (AUPH)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- Trump threatens to bomb Oman over Iran stance
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Micron rises as White House presses Apple to avoid Chinese memory chips
TD Cowen Reiterates Buy Rating on Aurinia Pharmaceuticals (AUPH)
June 30, 2025 1:09 PM EDTTD Cowen analyst Stacy Ku reiterated a Buy rating and $11.00 price target on Aurinia Pharmaceuticals (NASDAQ: AUPH).
The analyst comments "Phase I healthy volunteer SAD data for aritinercept/AUR200 (BAFF/April inhibitor) appear to be matching other competitive/BIC programs in development. Specifically, a single dose of aritinercept demonstrated max reduction from baseline of 20% for IgG, 48% for IgA, and 55% IgM at 225mg dose, and effects appear saturated at higher doses (225/300mg; details below). The PK/PD profile supports monthly subcutaneous dosing (half-life 6-8 days) - with... More
Aurinia Pharmaceuticals (AUPH) Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)
June 30, 2025 6:01 AM EDTAurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced positive results from a Phase 1 single-ascending-dose (SAD) study of aritinercept (AUR200), its dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL). The study investigated aritinercept doses of 5 mg, 25 mg, 75 mg, 150 mg, 225 mg and 300 mg and placebo, administered by subcutaneous injection, in 61 healthy subjects.
Aritinercept was well tolerated at all dose levels tested. There were no treatment-related Grade 3 adverse... More
